pharmaphorum

JANUARY 26, 2023

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129

Genome Genomics Genome Project Genetics 129

Drug Discovery World

JULY 25, 2024

Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target to treat or even prevent these cancers from developing. Inherited variants that disrupt the protein can increase a person’s lifetime risk of developing these cancers by up to 50%, typically occurring around middle age.

Genetics 52

Genetics Research Drugs Gene 52

Drug Discovery World

MARCH 7, 2023

As such, Qatar Biobank has emerged within this modernisation to act as a focal point for the country’s goal in preventive and personalised healthcare. It also fits with the country’s preventative health approach that it established in its 2017-2022 Public Health Strategy 5.

Biobanking 52

Biobanking Drugs Genome Genomics 52

pharmaphorum

DECEMBER 2, 2021

GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. Genetics, proteomics and digital pathology will be harnessed in order to understand the patterns of disease which vary amongst individuals, said GSK.

Biobanking 86

Biobanking Genome Genomics Genetics 86

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Genetics 52

Genetics Biobanking Protein Containment 52

The Pharma Data

JULY 15, 2021

The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Biobanking 52

Biobanking Genetics Protein Medicine 52